Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX:
TH) (NASDAQ: THTX), a biopharmaceutical company focused on the
development and commercialization of innovative therapies, today
announced receipt of the 2023 Industrial Research Sectoral Group
(RSRI) Innovation Award from the CQDM (formerly known as the Québec
Consortium for Drug Discovery) and the Association for the
Development of Research and Innovation of Québec (ADRIQ). The award
recognizes the company’s work, in partnership with world-renowned
cancer researcher Professor Borhane Annabi of the Université du
Québec à Montréal (UQAM), in demonstrating the preclinical efficacy
of its investigational peptide-drug conjugate TH1902 (sudocetaxel
zendusortide) against triple-negative breast cancer.
The award-winning research was funded by
Theratechnologies, the Canadian Cancer Society, and the CQDM.
Theratechnologies and Prof. Annabi received the award last night
(November 23) at the 2023 ADRIQ Innovation Awards Gala, at the
Palais des Congrès de Montréal.
“Together with our esteemed research partners,
we are pleased to be recognized with the prestigious RSRI award for
conducting inspiring preclinical research on sudocetaxel
zendusortide against triple-negative breast cancer,” said Christian
Marsolais, Ph.D., Senior Vice President, and Chief Medical Officer
at Theratechnologies. “Our ongoing collaboration with Prof. Borhane
Annabi has been invaluable to the development of a novel,
made-in-Québec anti-cancer strategy, and we are grateful to the
Canadian Cancer Society and the CQDM for supporting this important
research initiative.”
“We hope that our award-winning research helps
to inform future drug development and treatment of triple-negative
breast cancer, as it is the most aggressive form of breast cancer
and has a high risk of recurrence,” said Dr. Annabi, who is
Professor of Biochemistry and Director of the Chair in Cancer
Prevention and Treatment at UQAM. “I extend my thanks to the CQDM
and ADRIQ for recognizing this ground-breaking Québec-based
initiative, to Theratechnologies for being a steadfast research
partner, and to all who have funded and supported this critically
important research.”
Sudocetaxel zendusortide is a new chemical
entity that employs a cleavable linker to conjugate a proprietary
peptide to docetaxel, a well-established cytotoxic chemotherapeutic
agent used to treat many cancers. The peptide recognizes and
exploits the functions of sortilin, a receptor expressed on the
surface of several types of cancer cells, to rapidly internalize
the drug and bypass chemoresistance mechanisms. This approach
enables the development of a more specific cancer-targeting
strategy and reduces the side effects of chemotherapy. The U.S.
Food and Drug Administration (FDA) granted Fast Track designation
to sudocetaxel zendusortide as a single agent for the treatment of
all sortilin-positive recurrent advanced solid tumors that are
refractory to standard therapy. A Phase 1 clinical trial is
currently underway with five study sites simultaneously enrolling
patients in the U.S., as well as a Canadian site set to begin
recruitment at the Centre Hospitalier de l'Université de Montréal.
More information on the study can be found here.
“The success of our collaboration with Prof.
Annabi has led to the initiation of spin-off projects to explore
the potential of sudocetaxel zendusortide to further inhibit the
metastasis process, and to create a new conjugate for the treatment
of colorectal cancer,” Dr. Marsolais added. “With this innovative
therapy currently in clinical trials, Theratechnologies is now in
an excellent position to help make a difference for people living
with advanced cancers.”
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR+
at www.sedarplus.ca and on EDGAR at www.sec.gov.
Follow Theratechnologies
on Linkedin and Twitter.
About UQAM
Open and audacious, UQAM is a French-language
public university with an international reputation. It welcomes
more than 35,000 students and has more than 300,000 graduates. It
offers 350 programs, almost half of which are at the graduate
level. Its Faculty of Sciences trains a high-level young generation
committed to finding answers to the concerns of populations thanks
to the impact of its research activities and the partnerships that
result from them, particularly in the fields of chemistry and
biochemistry. For more information, please visit the
website: https://uqam.ca/en/information/about/
About CQDM
Facilitator of biopharma innovation.
CQDM is a not-for-profit biopharmaceutical
research consortium whose mission is to support and facilitate
multi-stakeholder collaborative R&D aimed at accelerating
the translation of innovative technologies into solutions that
address unmet medical needs, while generating significant benefits
for the Quebec and Canadian economy. For more information,
please visit the website: www.cqdm.org
About the Canadian Cancer Society
The Canadian Cancer Society works tirelessly to
save and improve lives. We fund the brightest minds in cancer
research. We provide a compassionate support system for all those
affected by cancer, across Canada and for all types of cancer. As
the voice for people who care about cancer, we work with
governments to shape a healthier society. No other organization
does all that we do to make lives better today and transform the
future of cancer forever. Help us make a difference. Call
1-888-939-3333 or visit cancer.ca today.
Forward-Looking Information
This press release contains forward-looking
statements and forward-looking information (collectively, the
“Forward-Looking Statements”) within the meaning of applicable
securities laws, that are based on management’s beliefs and
assumptions and on information currently available to it. You can
identify forward-looking statements by terms such as “may”, “will”,
“should”, “could”, “promising”, “would”, “outlook”, “believe”,
“plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the
negatives of these terms, or variations of them. The
Forward-Looking Statements contained in this press release include,
but are not limited to, statements regarding the enrollment,
recruitment and dosing of patients in the Company’s Phase 1
clinical trial studying sudocetaxel zendusortide and statements
regarding the development of new conjugates. Although the
Forward-Looking Statements contained in this press release are
based upon what the Company believes are reasonable assumptions in
light of the information currently available, investors are
cautioned against placing undue reliance on these statements since
actual results may vary from the Forward-Looking Statements
contained in this press release. Forward-Looking Statements
assumptions are subject to a number of risks and uncertainties,
many of which are beyond the Company’s control, that could cause
actual results to differ materially from those that are disclosed
in or implied by such Forward-Looking Statements. These risks and
uncertainties include, but are not limited to, the impossibility to
demonstrate the safe and effective use of sudocetaxel zendusortide
with the Company’s Phase 1 clinical trial and the inability of the
Company to obtain positive results from research and development
work resulting in the non-development of further conjugates. We
refer current and potential investors to the "Risk Factors" section
of our annual information form dated February 27, 2023, available
on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov as
an exhibit to our report on Form 40-F dated February 28, 2023 under
Theratechnologies’ public filings for additional risks regarding
the conduct of our business and Theratechnologies. The reader is
cautioned to consider these and other risks and uncertainties
carefully and not to put undue reliance on forward-looking
statements. Forward-looking statements reflect current expectations
regarding future events and speak only as of the date of this press
release and represent our expectations as of that date. The Company
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise, except as
may be required by applicable law.
Contacts:Media inquiries:Julie
SchneidermanSenior Director, Communications & Corporate
Affairscommunications@theratech.com1-514-336-7800
Investor inquiries:Phillipe Dubuc Senior Vice President and
Chief Financial Officerpdubuc@theratech.com438-315-6608
Theratechnologies (TSX:TH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Theratechnologies (TSX:TH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024